NCT06361927View on ClinicalTrials.gov

A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients

PHASE2RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

July 31, 2025

Conditions

NSCLC

Interventions

DRUG

SSGJ-707

bispecific antibody

Trial Locations (1)

Unknown

RECRUITING

The Hunan Cancer Hospital, Changsha

All Listed Sponsors

lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY